Generic Pharmaceutical Partnering Terms and Agreements 2010-2026
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.
This report provides details of the latest generic pharmaceutical agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review generic generic pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering generic pharmaceutical partnering deals.
The report presents financial deal term values for generic pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the generic pharmaceutical partnering field; both the leading deal values and most active generic pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 900 online deal records of actual generic pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of generic pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in generic pharmaceutical dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading generic pharmaceutical deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in generic pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of generic pharmaceutical deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of generic pharmaceutical partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of generic pharmaceutical partnering deals signed and announced since Jan 2010. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by generic pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in generic pharmaceutical partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of generic pharmaceutical technologies and products.
Key benefits
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 provides the reader with the following key benefits:
- In-depth understanding of generic pharmaceutical deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of generic pharmaceutical agreements with real life case studies
- Detailed access to actual generic pharmaceutical contracts entered into by leading biopharma companies
- Identify most active generic pharmaceutical dealmakers since 2010
- Insight into terms included in a generic pharmaceutical partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 is intended to provide the reader with an in-depth understanding and access to generic pharmaceutical trends and structure of deals entered into by leading companies worldwide.
Generic Pharmaceutical Partnering Terms and Agreements includes:
- Trends in generic pharmaceutical dealmaking in the biopharma industry since 2010
- Analysis of generic pharmaceutical deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life generic pharmaceutical deals
- Access to generic pharmaceutical contract documents
- Leading generic pharmaceutical deals by value since 2010
- Most active generic pharmaceutical dealmakers since 2010
In Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides comprehensive access to available deals and contract documents for generic pharmaceutical deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 provides the reader with the following key benefits:
- In-depth understanding of generic pharmaceutical deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of generic pharmaceutical agreements with real life case studies
- Detailed access to actual generic pharmaceutical contracts entered into by leading biopharma companies
- Identify most active generic pharmaceutical dealmakers since 2010
- Insight into terms included in a generic pharmaceutical partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Generic pharmaceutical dealmaking
2.1. Introduction
2.2. Generic pharmaceutical partnering over the years
2.3. Most active Generic pharmaceutical dealmakers
2.4. Generic pharmaceutical partnering by deal type
2.5. Generic pharmaceutical partnering by therapy area
2.6. Generic pharmaceutical partnering by technology type
2.7. Deal terms for Generic pharmaceutical partnering
2.7.1 Generic pharmaceutical partnering headline values
2.7.2 Generic pharmaceutical deal upfront payments
2.7.3 Generic pharmaceutical deal milestone payments
2.7.4 Generic pharmaceutical royalty rates
Chapter 3 – Leading Generic pharmaceutical deals
3.1. Introduction
3.2. Top Generic pharmaceutical deals by value
Chapter 4 – Most active Generic pharmaceutical dealmakers
4.1. Introduction
4.2. Most active Generic pharmaceutical dealmakers
4.3. Most active Generic pharmaceutical partnering company profiles
Chapter 5 – Generic pharmaceutical contracts dealmaking directory
5.1. Introduction
5.2. Generic pharmaceutical contracts dealmaking directory
Chapter 6 – Generic pharmaceutical dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Generic pharmaceutical deals by company A-Z
Appendix 2 – Generic pharmaceutical deals by stage of development
Appendix 3 – Generic pharmaceutical deals by deal type
Appendix 4 – Generic pharmaceutical deals by therapy area
Appendix 5 – Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Generic pharmaceutical partnering since 2010
Figure 2: Active Generic pharmaceutical dealmaking activity since 2010
Figure 3: Generic pharmaceutical partnering by deal type since 2010
Figure 4: Generic pharmaceutical partnering by disease type since 2010
Figure 5: Generic pharmaceutical partnering by technology type since 2010
Figure 6: Generic pharmaceutical deals with a headline value
Figure 7: Generic pharmaceutical deals with an upfront value
Figure 8: Generic pharmaceutical deals with a milestone value
Figure 9: Generic pharmaceutical deals with a royalty rate value
Figure 10: Top Generic pharmaceutical deals by value since 2010
Figure 11: Most active Generic pharmaceutical dealmakers since 2010
Pricing options
- $3,995: single-user encrypted access
- $5,995: multi-user (2-5 users) encrypted access
- $7,995: corporate (company-wide) unencrypted PDF
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd., based in Co. Durham, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
